THU0171 TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS – THE RESULTS OF RUSSIAN NATIONAL REGISTER OF PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TOFACITINIB. (June 2019)

• Record Type: Journal Article
• Authors: Gaydukova, Inna; Mazurov, V; Zhilyaev, Evgeniy; Grabovetskaya, Iuliia; Marusenko, Irina; Vasilenko, Elizaveta; Abdulganieva, Diana; Smitienko, Ilia; Misiyuk, Anna; Lukina, Galina; Knyazeva, Larisa; Kalinina, Elena; Samigullina, Ruzana; Bondareva, Irina; Yudina, Natalya; Lapkina, N; Nasonov, Evgeny
• Is Part Of: Annals of the rheumatic diseases. Volume 78(2019)Supplement 2
• Page Start: 359
• Page End: 360
• Publication Date: 2019-06
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2019-eular.5986
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Tofacitinib (TF) is an oral Janus Kinase inhibitor for the treatment of rheumatoid arthritis (RA). Objectives: To evaluate the one-year effectiveness of tofacitinib as first-line therapy in RA conventional synthetic (cs) DMARDs non-responders. Methods: Data from 415 patients from Russian national register of patients with RA treated with TF were analyzed. 119 RA patients, who had complete clinical and laboratory data from 4 consecutive visits after baseline with an interval of 3 months between the visits and who used the TF as first-line therapy after failure of cs DMARDs, were included. Treatment with any biologics ever was an exclusion criteria. Demographical (age, sex) and RA activity data (DAS28, SDAI, number of tender and swollen joints (NTJ, NSJ), erythrocytes sedimentation rate (ESR), C-reactive protein (CRP), and HAQ, EQ5D were collected, table 1 . Statistical analysis performed in SPSS2017. p-value <0.05 considered as significant. Results: At baseline 12 (10%) were treated with NSAIDs, 15 (12.6) with 5-10 mg/dayof prednisolone, 82 (68.9) – with methotrexate (10-25 mg/week), 8 (6.7%) – with sulfasalazine (2.0-3.0 g/day). Changes in the disease activity in patients with RA, treated with tofacitinib after csDMARD are presented in Table 2 At visit 3 DAS28 <3.2 achieved 80 (67.22%) of the patients: 71 patients on 20 mg of TF (59.66%) and 9 patients on 10 mg of TF 11 (9.24%) patients at visit 3 had DAS28 ≥5.1. Conclusion: Treatment with TF may provide good response rates in RA patients, refractory previous cs DMARDs. Acknowledgement: Study sponsored by Pfizer Disclosure of Interests: Inna Gaydukova Grant/research support from: JSC BIOCAD, Speakers bureau: paiment from Pfizer, Novartis, Abbvie, Biocad, Selgene, MSD, Sanofy does not exceed 10 000 euros, V Mazurov Grant/research support from: JSC BIOCAD, Evgeniy Zhilyaev: None declared, Iuliia Grabovetskaya: None declared, Irina Marusenko: None declared, Elizaveta Vasilenko: None declared, Diana Abdulganieva: None declared, Ilia Smitienko: None declared, Anna Misiyuk: None declared, Galina Lukina: None declared, Larisa Knyazeva: None declared, Elena Kalinina: None declared, Ruzana Samigullina: None declared, Irina Bondareva: None declared, Natalya Yudina: None declared, N Lapkina: None declared, Evgeny Nasonov: None declared